Theranos Under Scrutiny After WSJ Criticism

at 9:00 AM
Save ArticleSave Article

Failed to save article

Please try again

This article is more than 7 years old.
 (Andrew Burton/Getty Images)

Bay Area-based Theranos is coming under scrutiny after a Wall Street Journal article questioned the accuracy of the company's blood-testing technology. Since the article, plans for a $350 million partnership with Safeway fell through. Theranos, which is valued at $9 billion, hired a high-profile Supreme Court lawyer and is weighing a defamation lawsuit against the paper. We'll get the latest on Theranos and its recent interactions with the FDA and Capitol Hill.